Victory for Prostate Cancer Care: Abiraterone Access Expanded in England

For thousands of men living with prostate cancer in England, the start of 2026 has brought more than just a new year, it has brought the gift of time. In a landmark victory for patient advocacy and clinical common sense, NHS England has officially announced that the life-extending drug abiraterone will finally be made available to high-risk patients whose cancer has not yet spread.

This decision marks the end of a gruelling three-year campaign and effectively dismantles a "postcode lottery" that saw men in Scotland and Wales accessing the drug while those in England were left to wait, worry, or pay out of pocket.

Why Abiraterone is a Game-Changer

Abiraterone isn’t just another medication; it is a specialised type of hormone therapy that targets the very "fuel" prostate cancer needs to survive.

Most prostate cancers are hormone-sensitive, meaning they rely on testosterone to grow. While standard hormone therapies focus on the testicles, abiraterone is unique because it stops the body from producing testosterone everywhere, including within the cancer cells themselves.

The clinical evidence backing this expansion is staggering. Data from the long-running STAMPEDE trial revealed that for men with high-risk, non-metastatic prostate cancer, adding abiraterone to their treatment:

• Halves the risk of the cancer returning.

• Reduces the risk of death by 40%.

• Significantly increases the chances of a permanent cure.

For a disease that claims thousands of lives annually, these aren't just statistics—they represent grandfathers, fathers, and sons who will now be present for more birthdays and milestones.

The Human Cost of Bureaucracy

While the medical community celebrates, the victory is bittersweet for those who led the charge. Giles Turner, a patient from Brighton diagnosed with aggressive cancer in 2023, became the face of the campaign after discovering he was ineligible for the drug on the NHS simply because he lived in England.

"I was shocked and angered that my postcode meant I was denied free access to a treatment that could halve my risk of dying," Turner told the BBC. Fortunately, he was able to afford the £250 monthly cost to pay for it privately, but he remained "outraged" for the thousands of men who could not.

His "dogged and determined" efforts, alongside the charity Prostate Cancer UK, eventually broke through the bureaucratic wall. However, the timeline remains a point of frustration. Since abiraterone went "off-patent" in 2022—making it significantly cheaper—there was little commercial incentive for drug companies to navigate the complex NICE approval process for new uses. This left a gap where the science was ready, the drug was affordable, but the system was stuck.

Looking Ahead: What This Means for Patients

The impact of this rollout, expected to take effect within weeks, is massive:

• 7,000 men per year are estimated to be eligible for the treatment.

• 1,470 men will avoid the devastating news that their cancer has progressed.

• 560 lives are expected to be saved annually.

NHS England has confirmed that approximately 2,000 men diagnosed in the last three months will be among the first to gain access, provided there is a clear clinical benefit.

"This decision is a momentous, life-saving victory... It's terrifying to be told you've got a cancer that's likely to spread, then find out you can't access the best chance at surviving." — Amy Rylance, Prostate Cancer UK

The Final Frontier: Northern Ireland

While England joins Scotland and Wales in providing this care, the battle isn't entirely over. Northern Ireland remains the last part of the UK where this wider access is not yet routine. Prostate Cancer UK is currently engaging with decision-makers at Stormont to ensure that men in Northern Ireland aren't left behind in what remains of this geographic disparity.

A New Chapter in Cancer Care

The approval of abiraterone is a testament to the power of patient voices and the importance of clinical trials like STAMPEDE. It also highlights a necessary shift in how the NHS handles "off-patent" drugs that have proven, life-saving potential but lack a corporate sponsor to push them through the finish line.

For the 7,000 men who will start this treatment this year, the message is clear: the science is here, the funding is ready, and the postcode no longer determines the chance of a cure.